Supplement marketer Kevin Trudeau "cannot make disease or health benefits claims for any type of product, service, or program in any advertising...regardless of the format and duration," according to a settlement that also involves a $2 mil. monetary judgement, the Federal Trade Commission announces Sept. 7. Trudeau and partner Robert Barefoot were charged in June 2003 with making claims that the supplement Coral Calcium Supreme could cure cancer, heart disease and high blood pressure. Trudeau recently was found in contempt of court for violating a 2003 preliminary injunction that barred him from making the ad claims (1"The Tan Sheet" July 12, 2004, In Brief)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.
The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.
